Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Pediatric Nephrology
Erschienen in: Pediatric Nephrology 9/2012

01.09.2012 | Educational Review

The role of genetics in drug dosing

verfasst von: Nicholas Ware

Erschienen in: Pediatric Nephrology | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Renal transplantation is the optimal form of renal replacement therapy (RRT) for the majority of patients. Both short- and long-term graft rejection are well recognized complications following transplantation, and optimal immunosuppression is often difficult to achieve. Pharmacodynamics (PD) and pharmacokinetics (PK) are hard to predict in all patients, and best practice involves the use of standard dosing based on weight and therapeutic drug monitoring (TDM). Pharmacogenetics (PG) is the use of genetic screening to predict metabolic responses to different immunosuppressive drugs and enables more accurate predictions of PD and PK to be made. This has the potential to improve graft outcome by reducing both short- and long-term graft rejection.
Literatur
1.
Golshayan D, Buhler L, Lechler RI, Pascual M (2007) From current immunosuppressive strategies to clinical tolerance of allografts. Transpl Int 20:12–24PubMedCrossRef
2.
Kaneku HK, Terasaki PI (2006) Thirty year trend in kidney transplants: UCLA and UNOS Renal Transplant Registry. Clin Transpl 1–27
3.
Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351:2715–2729PubMedCrossRef
4.
Clase CM, Mahalati K, Kiberd BA, Lawen JG, West KA, Fraser AD, Belitsky P (2002) Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling. Am J Transplant 2:789–795PubMedCrossRef
5.
Undre NA, van Hoof J, Christiaans M, Vanrenterghem Y, Donck J, Heeman U, Kohnle M, Zanker B, Land W, Morales JM, Andres A, Schafer A, Stevenson P (1999) Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 31:296–298PubMedCrossRef
6.
van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le Meur Y, Oellerich M, Holt D, Tonschoff B, Keown B, Campbell S, Mamelok R (2008) Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixed-dose concentration-controlled trial. Transplantation 86:1043–1051PubMedCrossRef
7.
Hesselink DA, van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Zeier M, Budde K, Kuypers DR, Pisarski P, Le Meur Y, Mamelok RD, Van Gelder T (2008) CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 18:339–348PubMedCrossRef
8.
Le Meur Y, Djebli N, Szelag JC, Hoizey G, Toupance O, Rérolle JP, Marquet P (2006) CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 80:51–60PubMedCrossRef
9.
Ng FL, Holt DW, MacPhee IA (2007) Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. Expert Opin Pharmacother 8:2045–2058PubMedCrossRef
10.
Ekbal NJ, Holt DW, MacPhee IA (2008) Pharmacogenetics of immunosuppressive drugs: Prospect of individual therapy for transplant patients. Pharmacogenomics 9:585–596PubMedCrossRef
11.
Cattaneo D, Baldelli S, Perico N (2008) Pharmacogenetics of immunosuppressants: Progress, pitfalls and promises. Am J Transplant 8:1374–1383PubMedCrossRef
12.
Macphee IA, Holt DW (2008) A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. Transplantation 85:163–165PubMedCrossRef
13.
Zhang Y, Benet LZ (2001) The gut as a barrier to drug absorption. Combined role of cytochrome P4503A and P-glycoprotein. Clin Pharmacokinet 40:159–168PubMedCrossRef
14.
Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W, Kharasch ED, Thummel KE (2004) In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 68:1889–1902PubMedCrossRef
15.
Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, Thummel KE (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836–847PubMedCrossRef
16.
Kamdem LK, Streit F, Zanger UM, Brockmoller J, Oellerich M, Armstrong VW, Wojnowski L (2005) Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 51:1374–1381PubMedCrossRef
17.
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391PubMedCrossRef
18.
Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A (2004) CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 75:1059–1069PubMedCrossRef
19.
Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, Zaya MJ (2003) Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 307:573–582PubMedCrossRef
20.
Yukawa E (2007) Approach to individualized pharmacotherapy: analysis of population pharmacokinetic parameters. TDM Research 24:8–16
21.
Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW (2002) Tacrolimus pharmacogenetics: Polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74:1486–1489PubMedCrossRef
22.
Haufroid V, Wallemacq P, Vankerckhove V, Elens L, De Meyer M, Eddour DC, Malaise J, Lison D, Mourad M (2006) CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: Guidelines from an experimental study. Am J Transplant 6:2706–2713PubMedCrossRef
23.
MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW (2004) The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 4:914–919PubMedCrossRef
24.
Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y (2007) CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82:711–725PubMedCrossRef
25.
MacPhee IA, Fredericks S, Mohamed M, Moreton M, Carter ND, Johnston A, Goldberg L, Holt DW (2005) Tacrolimus pharmacogenetics: The CYP3A5*1 allele predicts low dose-normalised tacrolimus blood concentrations in whites and South Asians. Transplantation 79:499–502PubMedCrossRef
26.
Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, Taburet AM, Charpentier B, Becquemont L (2008) Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol 103:546–552PubMedCrossRef
27.
Chen JS, Li LS, Cheng DR, Ji SM, Sun QQ, Cheng Z, Wen JQ, Sha GZ, Liu ZH (2009) Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. Transplant Proc 41:1557–1561PubMedCrossRef
28.
Singh R, Srivastava A, Kapoor R, Sharma K, Mittal D (2009) Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmiedebergs Arch Pharmacol 380:169–177PubMedCrossRef
29.
Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, Loirat C, Cochat P, Cloarec S, André J, Garaix F, Bensman A, Fakhoury M, Jacqz-Aigrain E (2009) Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther 86:609–618PubMedCrossRef
30.
Ferraresso M, Tirelli A, Ghio L, Grillo P, Martina V, Torresani E, Edefonti A (2007) Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatric Transplant 11:296–300CrossRef
31.
Zheng HX, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, Burckart GJ (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplantation 3:477–483CrossRef
32.
Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng AE, Subra JF, Beaune P, Legendre C (2010) Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 87:721–726PubMed
33.
Kreutz R, Zurcher H, Kain S, Martus P, Offermann G, Beige J (2004) The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 14:665–671PubMedCrossRef
34.
Fredericks S, Jorga A, MacPhee IA, Reboux S, Shiferaw E, Moreton M, Carter ND, Holt DW, Johnston A (2007) Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. Clin Transplant 21:252–257PubMedCrossRef
35.
MacDonald A, Scarola J, Burke JT, Zimmerman JJ (2000) Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 22(Suppl B):B101–B121PubMedCrossRef
36.
Anglicheau D, Le Corre D, Lechaton S, Laurent-Puig P, Kreis H, Beaune P, Legendre C, Thervet E (2005) Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 5:595–603PubMedCrossRef
37.
Miao LY, Huang CR, Hou JQ, Qian MY (2007) Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 29:1–5CrossRef
38.
Mourad M, Mourad G, Wallemacq P, Garrigue V, Van Bellingen C, Van KV, De Meyer M, Malaise J, Eddour DC, Lison D, Squifflet JP, Haufroid V (2005) Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 80:977–984PubMedCrossRef
39.
Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi L (2007) CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 81:228–234PubMedCrossRef
40.
Webster AC, Lee VW, Chapman JR, Craig JC (2006) Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 81:1234–1248PubMedCrossRef
41.
Saeki T, Ueda K, Tanagawara Y, Hori R, Komano T (1993) Human P-glycoprotein transports cyclosporin A and FK505. J Biol Chem 268:6077–6080PubMed
42.
Miller DS, Fricker G, Drewe J (1997) p-Glycoprotein-mediated transport of a fluorescent rapamycin derivative in renal proximal tubule. J Pharmacol Exp Ther 282:440–444PubMed
43.
Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 75:13–33PubMedCrossRef
44.
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478PubMed
45.
Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter M-H, Cassinat B, Beaune P, Legendre C, Thervet E (2003) Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14:1889–1896PubMedCrossRef
46.
Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525–528PubMedCrossRef
47.
Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693–704PubMedCrossRef
48.
Chowbay B, Li H, David M, Cheung YB, Lee EJ (2005) Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 60:159–171PubMedCrossRef
49.
Masuda S, Goto M, Fukatsu S, Uesugi M, Ogura Y, Oike F, Kiuchi T, Takada Y, Tanaka K, Inui K (2006) Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin Pharmacol Ther 79:90–102PubMedCrossRef
50.
Hawwa AF, McKiernan PJ, Shields M, Millership JS, Collier PS, McElnay JC (2009) Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol 68:413–421PubMedCrossRef
51.
Cattaneo D, Ruggenenti P, Baldelli S, Motterlini N, Gotti E, Sandrini S, Salvadori M, Segoloni G, Rigotti P, Donati D, Perico N, Remuzzi G (2009) ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J Am Soc Nephrol 20:1404–1415PubMedCrossRef
52.
Fanta S, Niemi M, Jönsson S, Karlsson MO, Holmberg C, Neuvonen PJ, Hoppu K, Backman JT (2008) Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics 18:77–90PubMedCrossRef
53.
Dintaman JM, Silverman JA (1999) Inhibition of P-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 16:1550–1556PubMedCrossRef
54.
Evans WE (2004) Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 26:186–191PubMedCrossRef
55.
Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Habuchi T, Suzuki T (2008) Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids 73:1052–1059PubMedCrossRef
56.
Miki Y, Suzuki T, Tazawa C, Blumberg B, Sasano H (2005) Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol Cell Endocrinol 231:75–85PubMedCrossRef
57.
Zheng HX, Webber SA, Zeevi A, Schuetz E, Zhang J, Lamba J, Boyle GJ, Wilson JW, Burckart GJ (2004) The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis. Pediatr Transplant 8:551–557PubMedCrossRef
58.
Middleton PG, Taylor PR, Jackson G, Proctor SJ, Dickinson AM (1998) Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 92:3943–3948PubMed
59.
Benkali K, Prémaud A, Picard N, Rérolle JP, Toupance O, Hoizey G, Turcant A, Villemain F, Le Meur Y, Marquet P, Rousseau A (2009) Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 48:805–816PubMedCrossRef
60.
Li L, Li CJ, Zheng L, Zhang YJ, Jiang HX, Si-Tu B, Li Z (2011) Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study. Eur J Clin Pharmacol 67:787–795PubMedCrossRef
61.
Sombogaard F, van Schaik RH, Mathot RA, Budde K, van der WM, Vulto AG, Weimar W, Glander P, Essioux L, van Gelder T (2009) Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism. Pharmacogenet Genomics 19:626–634PubMedCrossRef
62.
Grinyo J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K, Rashford M, Nasmyth-Miller C, Voulgari A, Spleiss O, Truman M, Essioux L (2008) Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 21:879–891PubMedCrossRef
63.
Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R, Fu J, Shah T, Pravica V, Hutchinson IV, Burckart GJ (2008) IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 83:711–717PubMedCrossRef
64.
Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y (2006) Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82:1074–1084PubMedCrossRef
65.
van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, Kuypers D, Le Meur Y, van der WM, Mamelok R, van Gelder T (2009) UGT1A9–275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther 86:319–327PubMedCrossRef
66.
Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y (2005) The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 78:351–361PubMedCrossRef
67.
Mirochnick M, Capparelli E, Connor J (1999) Pharmacokinetics of zidovudine in infants: a population analysis across studies. Clin Pharmacol Ther 66:16–24PubMedCrossRef
68.
Crettol S, Venetz JP, Fontana M, Aubert JD, Ansermot N, Fathi M, Pascual M, Eap CB (2008) Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics 18:307–315PubMedCrossRef
69.
Ansermot N, Rebsamen M, Chabert J, Fathi M, Gex-Fabry M, Daali Y, Besson M, Rossier M, Rudaz S, Hochstrasser D, Dayer P, Desmeules J (2008) Influence of ABCB1 gene polymorphisms and P-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers. Drug Metab Lett 2:76–82PubMedCrossRef
70.
Barbari AG, Masri MA, Stephan AG, El Ghoul B, Rizk S, Mourad N, Kamel GS, Kilani HE, Karam AS (2006) Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: A prospective study. Exp Clin Transplant 4:400–405PubMed
71.
Falck P, Guldseth H, Asberg A, Midtvedt K, Reubsaet JL (2007) Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 852:345–352PubMedCrossRef
72.
Capron A, Musuamba F, Latinne D, Mourad M, Lerut J, Haufroid V, Wallemacq PE (2009) Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in peripheral blood mononuclear cells. Ther Drug Monit 31:178–186PubMedCrossRef
73.
Falck P, Asberg A, Guldseth H, Bremer S, Akhlaghi F, Reubsaet JL, Pfeffer P, Hartmann A, Midtvedt K (2008) Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients. Transplantation 85:179–184PubMedCrossRef
74.
Singh D, Alexander J, Owen A, Rustom R, Bone M, Hammad A, Roberts N, Park K, Pirmohamed M (2004) Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. Transplantation 77:557–561PubMedCrossRef
75.
Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, Viklicky O (2008) Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation 86:1206–1213PubMedCrossRef
76.
Hebert MF, Dowling AL, Gierwatowski C, Lin YS, Edwards KL, Davis CL, Marsh CL, Schuetz EG, Thummel KE (2003) Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 13:661–674PubMedCrossRef
77.
Woodahl EL, Hingorani SR, Wang J, Guthrie KA, McDonald GB, Batchelder A, Li M, Schoch HG, McCune JS (2008) Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation. Pharmacogenomics J 8:248–255PubMedCrossRef
78.
Klauke B, Wirth A, Zittermann A, Bohms B, Tenderich G, Korfer R, Milting H (2008) No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation. J Heart Lung Transplant 27:741–745PubMedCrossRef
79.
Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, Ackermann H, Seidl C, Hocher B, Zanger UM, Geiger H, Eichelbaum M, Schwab M (2005) ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 16:1501–1511PubMedCrossRef
80.
Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF (2005) Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Pharmacotherapy 25:779–789PubMedCrossRef
81.
Anglicheau D, Pallet N, Rabant M, Marquet P, Cassinat B, Meria P, Beaune P, Legendre C, Thervet E (2006) Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 70:1019–1025PubMedCrossRef
82.
Goldfarb-Rumyantzev AS, Naiman N (2010) Genetic predictors of acute renal transplant rejection. Nephrol Dial Transplant 25:1039–1047PubMedCrossRef
83.
Woillard JB, Rerolle JP, Picard N, Rousseau A, Guillaudeau A, Munteanu E, Essig M, Drouet M, Le Meur Y, Marquet P (2010) Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up. Clin Pharmacol Ther 88:95–100PubMedCrossRef
84.
Kausman JY, Patel B, Marks SD (2008) Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients. Pediatr Transplant 12:329–335PubMedCrossRef
Metadaten
Titel
The role of genetics in drug dosing
verfasst von
Nicholas Ware
Publikationsdatum
01.09.2012
Verlag
Springer-Verlag
Erschienen in
Pediatric Nephrology / Ausgabe 9/2012
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-012-2105-0

Weitere Artikel der Ausgabe 9/2012

Pediatric Nephrology 9/2012 Zur Ausgabe

Review

Nutrition in infants and very young children with chronic kidney disease

Original Article

C1GALT1 polymorphisms are associated with Henoch–Schönlein purpura nephritis

Brief Report

Post-transplantation encapsulating peritoneal sclerosis in a pediatric patient

Clinical Quiz

Hyperkalaemia in a female patient with systemic lupus erythematosus: answers

Brief Report

GLCCI1 single nucleotide polymorphisms in pediatric nephrotic syndrome

Brief Report

Early renal abnormalities in children with postnatally diagnosed autosomal dominant polycystic kidney disease

Neu im Fachgebiet Pädiatrie

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise